The short-term effects of head-mounted virtual-reality on neuropathic pain intensity in people with spinal cord injury pain: a randomised cross-over pilot study

• Published in: Spinal cord Vol. 59; no. 7; pp. 738 - 746
• Main Authors: Austin, Philip D., Craig, Ashley, Middleton, James W., Tran, Yvonne, Costa, Daniel S. J., Wrigley, Paul J., Siddall, Philip J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.07.2021; Nature Publishing Group
• Subjects: 692/1807/410/2610; 692/308/2779/109/1940; 692/700/228/491; Anatomy; Biomedical and Life Sciences; Biomedicine; Computer applications; Drug therapy; Human Physiology; Neuralgia; Neurochemistry; Neuropsychology; Neurosciences; Pain; Spinal cord injuries; Virtual reality
• ISSN: 1362-4393; 1476-5624; 1476-5624
• DOI: 10.1038/s41393-020-00569-2

Study design Within-subject, randomised cross-over trial. Objectives To determine whether a commercially available 3D head-mounted (HMD) virtual reality (VR) device results in significant reductions in neuropathic pain compared to using a 2D screen device in people with spinal cord injury (SCI). Setting Greenwich Hospital, Sydney, Australia. Methods Sixteen men with established SCI and chronic neuropathic pain participated in a single-session randomised cross-over trial. We compared the effects of 3D HMD VR and a 2D screen application on SCI neuropathic pain intensity and levels of perceived presence. Results Participants reported significantly lower pain intensity after 3D HMD VR compared to 2D screen application (1.9 ± SD 1.8 versus 3.4 ± SD 1.6, mean 95% CI: 1.5, P  < 0.0001). Participants reported significantly higher perceived levels of presence with the 3D HMD VR compared to 2D screen of (49.6 ± SD 8.9 versus 32.8 ± SD 11.1, mean 95% CI: 16.6, P  < 0.0001). Increased perceived presence was associated with significantly lower pain intensity regardless of randomised sequencing of the two conditions (mean 95% CI: 0.06, P  = 0.005). Effect size for pain reduction using 3D HMD VR was 0.80. Conclusions We suggest that 3D HMD VR may provide neuropathic pain relief for people with SCI. Given the lack of cybersickness and ease of access, we propose that immersive VR could be a helpful adjunct to current pharmacotherapy. Further research is required to show that VR can be effective for more long-term reductions in SCI pain.